AntriaBio

Financials

Investors

Financials

v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
Dec. 31, 2018
Jun. 30, 2018
Current assets:    
Cash $ 258,188 $ 1,645,872
Assets held for sale 72,537 0
Other current assets 91,553 361,915
Total current assets 422,278 2,007,787
Non-current assets:    
Intangibile assets, net 33,384 37,030
Fixed assets, net 0 368,374
Lease deposits and other 0 89,691
Total assets 455,662 2,502,882
Current liabilities:    
Accounts payable and accrued expenses 2,091,017 1,706,154
Accrued payroll 872,431 770,976
Convertible notes payable, net 10,000 3,434,611
Interest payable 2,762 148,372
Embedded derivative liability 0 73,904
Deferred lease liability 0 113,997
Total current liabilities 2,976,210 6,248,014
Non-current liabilities:    
Convertible notes payable, net 5,005,774 0
Interest payable on convertible notes payable 761,372 0
Exclusivity Payment 1,500,000 0
Long-term portion of deferred lease liability 0 190,577
Sublease deposit liability 0 25,046
Total liabilities 10,243,356 6,463,637
Commitments and contingencies (Notes 10 and 11)
Stockholders' deficit:    
Preferred stock, $0.001 par value; 20,000,000 shares authorized; 15,000,000 shares designated as Series A; no shares issued 0 0
Common stock, $0.001 par value, 200,000,000 shares authorized; 61,866,319 and 62,166,309 shares issued and outstanding as of December 31, 2018 and June 30, 2018, respectively 61,869 62,168
Additional paid-in capital 91,860,840 90,160,815
Accumulated deficit (101,710,403) (94,183,738)
Total stockholders' deficit (9,787,694) (3,960,755)
Total liabilities and stockholders' deficit $ 455,662 $ 2,502,882
v3.10.0.1
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 6 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Research and development:        
Compensation and benefits $ 371,428 $ 1,482,946 $ 928,819 $ 2,983,810
Consultants and outside costs 126,457 233,798 173,162 364,159
Material manufacturing costs 472,589 227,602 545,521 653,691
Facilities and other costs 288,072 479,149 537,769 981,807
Total research and development 1,309,093 3,413,088 2,239,002 7,723,726
General and administrative:        
Compensation and benefits 1,381,852 1,672,494 2,631,548 3,467,921
Professional fees 85,618 213,399 207,541 436,993
Investor relations 13,947 133,705 57,960 193,576
Other general and administrative 291,721 318,272 531,061 645,872
Loss on sale of fixed assets 45,679 0 22,827 0
Impairment of long-lived assets 33,039 0 33,039 0
Total general and administrative 1,851,856 2,337,870 3,483,976 4,744,362
Operating loss (3,160,949) (5,750,958) (5,722,978) (12,468,088)
Non-operating income (expense):        
Interest income 35 524 63 861
Gain on lease termination 167,788 0 167,788 0
Rent income 63,605 31,838 153,071 63,676
Interest expense (1,286,911) (147) (2,198,513) (147)
Derivative gains 55,000 156 73,904 498
Total non-operating income (expense) (1,000,483) 32,371 (1,803,687) 64,888
Net loss $ (4,161,432) $ (5,718,587) $ (7,526,665) $ (12,403,200)
Net loss per common share - basic and diluted $ (0.07) $ (0.11) $ (0.12) $ (0.23)
Weighted average number of common shares outstanding - basic and diluted 62,123,919 53,762,538 62,144,998 53,327,558
Clinical trial costs        
Research and development:        
Cost of Goods and Services Sold $ 547 $ 581,988 $ 3,731 $ 1,561,754
License costs        
Research and development:        
Cost of Goods and Services Sold $ 50,000 $ 407,605 $ 50,000 $ 1,178,505
v3.10.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
6 Months Ended
Dec. 31, 2018
Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (7,526,665) $ (12,403,200)
Amortization of intangible assets 3,646 3,646
Accretion of debt discount and issuance costs 1,581,163 0
Depreciation and amortization expense 38,832 533,394
Gain on lease termination (167,788) 0
Loss on sale of fixed assets 22,827 0
Impairment of long-lived assets 33,039 0
Stock-based compensation expense 1,693,369 2,701,728
Derivative gains (73,904) (498)
Fair value of warrants issued to consultants 6,357 535,303
Changes in operating assets and liabilities:    
Decrease in other assets 264,173 146,287
Decrease (increase) in deferred lease asset (14,926) 11,462
Increase in accounts payable and accrued expenses 486,318 469,177
Increase in interest payable 615,762 0
Decrease in deferred lease liability (45,026) (49,950)
Net Cash Used In Operating Activities (3,082,823) (8,052,651)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Proceeds from sale of equipment 195,139 0
Purchase of fixed assets 0 (5,816)
Net Cash Provided By (Used In) Investing Activities 195,139 (5,816)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from Series AA financing Exclusivity Payment 1,500,000 0
Proceeds from issuance of common stock 0 4,500,000
Payment of offering costs 0 (60,000)
Net Cash Provided by Financing Activities 1,500,000 4,440,000
Net decrease in cash (1,387,684) (3,618,467)
Cash at beginning of period 1,645,872 4,486,538
Cash at end of period 258,188 868,071
Cash paid for    
Interest 0 0
Income taxes 0 0
Non-Cash Investing and Financing Activities:    
Transfer of fixed assets to assets held for sale 72,537 0
Shareholder surrender of 299,990 shares for no consideration $ 0 $ 0